CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume
- PMID: 30555890
- PMCID: PMC6280588
- DOI: 10.1016/j.dadm.2018.10.003
CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume
Abstract
Introduction: We examined the association between cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease, neural novelty responses, and brain volume in predementia old age.
Methods: We conducted a cross-sectional analysis of the observational, multicentric DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE) study. Seventy-six participants completed task functional magnetic resonance imaging and provided CSF (40 cognitively unimpaired, 21 experiencing subjective cognitive decline, and 15 with mild cognitive impairment). We assessed the correlation between CSF biomarkers and whole-brain functional magnetic resonance imaging novelty responses to scene images.
Results: Total tau levels were specifically and negatively associated with novelty responses in the right amygdala and right hippocampus. Mediation analyses showed no evidence that these associations were dependent on the volume of hippocampus/amygdala. No relationship was found between phosphorylated-tau or Aβ42 levels and novelty responses.
Discussion: Our data show that CSF levels of total tau are associated with anatomically specific reductions in novelty processing, which cannot be fully explained by atrophy.
Keywords: Alzheimer's disease (AD); Apolipoprotein E (APOE); Aβ42; Cerebrospinal fluid (CSF); Longitudinal; Magnetic resonance imaging (MRI); Mild cognitive impairment (MCI); Positron emission tomography (PET); Subjective cognitive decline (SCD); Tau.
Figures



Similar articles
-
Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction.Brain. 2022 May 24;145(4):1473-1485. doi: 10.1093/brain/awab405. Brain. 2022. PMID: 35352105 Free PMC article.
-
Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).Alzheimers Res Ther. 2018 Feb 7;10(1):15. doi: 10.1186/s13195-017-0314-2. Alzheimers Res Ther. 2018. PMID: 29415768 Free PMC article.
-
Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease.Front Aging Neurosci. 2017 Feb 7;9:9. doi: 10.3389/fnagi.2017.00009. eCollection 2017. Front Aging Neurosci. 2017. PMID: 28223932 Free PMC article.
-
Biomarkers of Alzheimer's Disease and Cerebrovascular Lesions and Clinical Progression in Patients with Subjective Cognitive Decline: A Systematic Review.J Alzheimers Dis. 2021;83(3):1089-1111. doi: 10.3233/JAD-210218. J Alzheimers Dis. 2021. PMID: 34397412
-
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Alzheimers Dement. 2008. PMID: 18631949 Review.
Cited by
-
Reduced expression of fMRI subsequent memory effects with increasing severity across the Alzheimer's disease risk spectrum.Imaging Neurosci (Camb). 2024 Aug 20;2:imag-2-00260. doi: 10.1162/imag_a_00260. eCollection 2024. Imaging Neurosci (Camb). 2024. PMID: 40800283 Free PMC article.
-
Reduced Repetition Suppression in Aging is Driven by Tau-Related Hyperactivity in Medial Temporal Lobe.J Neurosci. 2021 Apr 28;41(17):3917-3931. doi: 10.1523/JNEUROSCI.2504-20.2021. Epub 2021 Mar 17. J Neurosci. 2021. PMID: 33731446 Free PMC article.
-
Feasibility of Digital Memory Assessments in an Unsupervised and Remote Study Setting.Front Digit Health. 2022 May 26;4:892997. doi: 10.3389/fdgth.2022.892997. eCollection 2022. Front Digit Health. 2022. PMID: 35721797 Free PMC article.
-
A comprehensive score reflecting memory-related fMRI activations and deactivations as potential biomarker for neurocognitive aging.Hum Brain Mapp. 2021 Oct 1;42(14):4478-4496. doi: 10.1002/hbm.25559. Epub 2021 Jun 16. Hum Brain Mapp. 2021. PMID: 34132437 Free PMC article.
-
Single-value scores of memory-related brain activity reflect dissociable neuropsychological and anatomical signatures of neurocognitive aging.Hum Brain Mapp. 2023 Jun 1;44(8):3283-3301. doi: 10.1002/hbm.26281. Epub 2023 Mar 27. Hum Brain Mapp. 2023. PMID: 36972323 Free PMC article.
References
-
- Selkoe D.J. Alzheimer's disease is a synaptic failure. Science. 2002;298:789–791. - PubMed
-
- Holtzman D.M., Goate A., Kelly J., Sperling R. Mapping the road forward in Alzheimer's disease. Sci Transl Med. 2011;3:114ps48. - PubMed
-
- Motter n., Pelfrey V.C., Kholodenko D., Barbour R., Wood J.K., Galasko D. Reduction of amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38:643–648. - PubMed
-
- Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–144. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous